ArticleDiscover nano2026
Bioinspired NiCoO
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A green synthetic approach was developed for the preparation of a NiCoO₂ nanocomposite using an aqueous extract of Moringa oleifera as both a reducing and stabilizing agent. The synthesized NiCoO₂ nanocomposite exhibited high crystallinity and measurable antimicrobial activity. Detailed characterization using XRD, UV-visible spectroscopy, fluorescence spectroscopy, FTIR, BET, SEM, EDS, elemental mapping, and TEM analyses confirmed its crystalline structure, elemental composition, thermal stability, surface functional groups, and morphological features. The nanocomposite and the synthesized products were evaluated for antimicrobial activity against S. aureus, B. cereus, P. vulgaris, and S. typhimurium, demonstrating inhibitory effects against the tested microorganisms. The NiCoO₂ nanocomposite was also employed as a heterogeneous catalyst in a one-pot multicomponent condensation reaction of aldehydes, hydrazine hydrate, barbituric acid, and ethyl acetoacetate under ultrasonic conditions, affording pyrazolopyrano[2,3-d]pyrimidine derivatives in yields of up to 98% within short reaction times. The catalyst retained its activity over five consecutive cycles, indicating good recyclability. Furthermore, the synthesized heterocycles exhibited antimicrobial activity against both Gram-positive and Gram-negative bacterial strains. Molecular docking studies revealed that all synthesized compounds (1-11) exhibited favorable binding affinities toward the 4COX enzyme, with docking scores higher than that of the reference drug indomethacin, suggesting their potential for further biological evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.